Improved alpha interferon composition and method for its production from human peripheral blood leukocytes

PCT No. PCT/US93/01135 Sec. 371 Date Oct. 5, 1993 Sec. 102(e) Date Oct. 5, 1993 PCT Filed Feb. 9, 1993 PCT Pub. No. WO93/16107 PCT Pub. Date Aug. 19, 1993.This invention provides a novel improved alpha interferon composition characterized by high specific activity, a purity of greater than 95% and w...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	MEI-JUNE LIAO, DOUGLAS TESTA, KATALIN FERENCZ-BIRO, ABBAS RASHIDBAIGI, MARIO DIPAOLA, MANISHA PADHYE
Format:	Patent
Sprache:	eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	PCT No. PCT/US93/01135 Sec. 371 Date Oct. 5, 1993 Sec. 102(e) Date Oct. 5, 1993 PCT Filed Feb. 9, 1993 PCT Pub. No. WO93/16107 PCT Pub. Date Aug. 19, 1993.This invention provides a novel improved alpha interferon composition characterized by high specific activity, a purity of greater than 95% and which upon use in humans is further characterized by a substantial reduction in side effects normally associated with alpha interferon compositions. Also provided is a method for large scale production of the composition from human peripheral blood leukocytes. This alpha interferon composition may be used therapeutically in the treatment of cancers and diseases of the immune system and/or viral etiology.